Eom Pharmaceutical Holdings IncOOTC IMUC Stock Report

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. The company is headquartered in Westlake Village, California and currently employs 3 full-time employees. The company went IPO on 2006-09-19. The firm is focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. The Company’s portfolio consists of two product candidates: EOM613 and EOM147. EOM613 is an investigational, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and, based on past clinical data, have both an anti-inflammatory and pro-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect when needed. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM is designed to counteract with the severe inflammatory effects of viruses, such as a cytokine storm or hyperimmune response following infection with the novel coronavirus that cause COVID-19.